J&J Pits Medivir's TMC435 Against Vertex's Incivek

Johnson & Johnson, in a sense, is going head to head with itself by pitting its investigational protease inhibitor, TMC435, which it in-licensed from Medivir AB, against telaprevir, the hepatitis C virus (HCV) drug it markets as Incivo in Europe, Latin America, India and several other regions, in a Phase III trial.